Press releasePRNewswire
Syros Pharmaceuticals
SYRS · OTC
$0.0004+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0004
Latest news
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results
- NewsRishabh Mishra
US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert
- Press releaseBusiness Wire
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings
- NewsVandana Singh
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
- NewsAvi Kapoor
US Stocks Mixed; Inflation Rate Increases In October
- NewsAvi Kapoor
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
- Press releaseBusiness Wire
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
- Press releaseBusiness Wire
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
- Press releaseBusiness Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
- Press releasePRNewswire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
- Press releaseBusiness Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
- Press releaseBusiness Wire
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
- Press releasePRNewswire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
- Press releaseBusiness Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
- NewsAvi Kapoor
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
- NewsAvi Kapoor
S&P 500 Gains 1%; Home Depot Earnings Top Views
- NewsAvi Kapoor
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
- Press releaseBusiness Wire
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
- Press releaseBusiness Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
- Press releasePRNewswire
Alltrna Announces Updates to Its Board of Directors
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.